Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xufol-Plus is a branded generic pharmaceutical combination product developed and marketed by Zaiva Lifesciences, an Indian pharmaceutical company. It is an oral tablet formulation designed as an enhanced version of the company's standard Xufol product. While the specific additional ingredients in the "Plus" formulation are not explicitly detailed in all available literature, the base Xufol formulation consists of L-methylfolate, methylcobalamin, and pyridoxal 5-phosphate. These components are bioactive forms of folate (Vitamin B9), Vitamin B12, and Vitamin B6, respectively. They serve as critical cofactors in the methionine cycle and the transsulfuration pathway, facilitating DNA synthesis, red blood cell maturation, and the regulation of homocysteine levels. Xufol-Plus is primarily indicated for the management of nutritional deficiencies, iron deficiency anemia, and nutritional support during pregnancy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Xufol-Plus.